Researchers from the National Cancer Institute have published a case report of a woman with KRAS-mutant metastatic colorectal cancer who had a nine-month remission after being treated with an autologous transplant of tumor-infiltrating lymphocytes. Read More
Emergent Biosolutions Inc. has lined up federal support for follow-on purchases of up to $1.1 billion of its anthrax vaccines that will keep the strategic national stockpile fresh as the government prepares for an anticipated 2019 transition. Read More
Shares of Synergy Pharmaceuticals Inc. popped early to a one-year high of $6.28 Friday after the company reported top-line data from the first of two pivotal phase III trials of plecanatide in adults with irritable bowel syndrome with constipation (IBS-C). Read More
HONG KONG – A world-first periodontitis vaccine that has been developed by Australian scientists, which could reduce or possibly even eliminate the need for surgery and antibiotics for the management of severe gum disease, has been validated by research published online Dec. 1, 2016, in npj Vaccines. Read More
LONDON – The EMA is facing widespread reservations about adaptive pathways as it moves to translate the accelerated route into its regular approval processes, following a two-year pilot. Read More
PERTH, Australia – The Australian government is making good on its promise to invest in innovation with Prime Minister Malcolm Turnball announcing nearly A$1 billion (US$744.6 million) in new grants and funds to build stronger national networks in translational science. Read More
HONG KONG – Boehringer Ingelheim GmbH and China Southeast University Institute of Life Sciences are spearheading a research project to develop new treatments for hearing loss through regeneration of hair cells from inner ear stem cells. Read More
Astrazeneca plc, of London, said the FDA has accepted the BLA for durvalumab, a PD-L1 human monoclonal antibody for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed during or after one standard platinum-based regimen. Read More
Sangamo Biosciences Inc., of Richmond, Calif., appointed Edward R. Conner senior vice president and chief medical officer, and Curt Herberts senior vice president and chief business officer. Read More
Cytokinetics Inc., of South San Francisco, shared patient baseline characteristics from its phase III study of tirasemtiv, VITALITY-ALS, and results of an international physician survey on the use of noninvasive ventilation in the treatment of amyotrophic lateral sclerosis (ALS) during the International Symposium on ALS/MND (motor neuron disease) in Dublin. Read More
